http://www.biocentury.com/rss/scibxSciBX: Science-Business eXchangeen-US© Copyright 2013 BioCentury, Inc.RSS Generatorhttp://www.biocentury.com/Data/NewsCenter2/Images/SciBX/CoverStory.gifhttp://www.biocentury.com/rss/scibxhttp://www.biocentury.com/scibx/coverstory/2013-06-13/cover-story-personalizing-cystic-fibrosis-in-vitro-s1http://www.biocentury.com/scibx/coverstory/2013-06-13/cover-story-personalizing-cystic-fibrosis-in-vitro-s1Cover StoryA team at University Medical Center Utrecht has developed a rapid and quantitative in vitro intestinal cell-based assay for function of cystic fibrosis transmembrane conductance regulator that could help identify …Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/targetsmechanisms/2013-06-13/pnag-broadening-infection-protection-table-1-adding-pathogens-to-the-pnag-list-s6bhttp://www.biocentury.com/scibx/targetsmechanisms/2013-06-13/pnag-broadening-infection-protection-table-1-adding-pathogens-to-the-pnag-list-s6bTargets & MechanismsPNAG: broadening infection protection Table 1. Adding pathogens to the PNAG list. A study in Proceedings of the National Academy of Sciences1 has added 24 more species of Gram-positive bacteria, Gram-negative …Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/targetsmechanisms/2013-06-13/pnag-broadening-infection-protection-table-2-nine-out-of-ten-for-pnag-s7http://www.biocentury.com/scibx/targetsmechanisms/2013-06-13/pnag-broadening-infection-protection-table-2-nine-out-of-ten-for-pnag-s7Targets & MechanismsPNAG: broadening infection protection Table 2. . Multiple studies have determined that the surface antigen poly-N-acetylglucosamine (PNAG) is expressed on all but one of the pathogens responsible for the 10 most …Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/targetsmechanisms/2013-06-13/targets-and-mechanisms-pnag-broadening-infection-protection-s6ahttp://www.biocentury.com/scibx/targetsmechanisms/2013-06-13/targets-and-mechanisms-pnag-broadening-infection-protection-s6aTargets & MechanismsA multi-institutional team has added more than 20 pathogens to the list of known bacteria that express the capsule polysaccharide poly-N-acetylglucosamine. The findings open up new indications for Alopexx Vaccine and …Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/targetsmechanisms/2013-06-13/targets-and-mechanisms-shrinking-old-hearts-s8http://www.biocentury.com/scibx/targetsmechanisms/2013-06-13/targets-and-mechanisms-shrinking-old-hearts-s8Targets & MechanismsBoston researchers have discovered a blood-borne protein called growth differentiation factor 11 that can reverse age-related cardiac hypertrophy in mice. The protein could be used as a therapeutic agent once its long-…Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-06-13/the-distillery-techniques-s17ahttp://www.biocentury.com/scibx/techniques/2013-06-13/the-distillery-techniques-s17aTechniquesThis week in techniques Approach Summary Licensing status Publication and contact information Assays & screens Screening platform for detecting RAF dimerization in cells A high throughput screening platform for…Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-06-13/the-distillery-techniques-s17bhttp://www.biocentury.com/scibx/techniques/2013-06-13/the-distillery-techniques-s17bTechniquesThis week in techniques Approach Summary Licensing status Publication and contact information Computational models Database of human phosphatase-substrate interactions A compilation of protein phosphatase-…Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-06-13/the-distillery-techniques-s17chttp://www.biocentury.com/scibx/techniques/2013-06-13/the-distillery-techniques-s17cTechniquesThis week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Human embryonic stem cell (hESC)-derived thymic epithelial cells capable of supporting T cell …Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-06-13/the-distillery-techniques-s17dhttp://www.biocentury.com/scibx/techniques/2013-06-13/the-distillery-techniques-s17dTechniquesThis week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Phage display system for rapid mammalian expression of library hits A phage display system designed …Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10ahttp://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10aTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune CD4; CD52; sialic acid binding Ig-like lectin 10 (SIGLEC10)…Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10bhttp://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10bTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) Ciliary neurotrophic factor (CNTF) In vitro …Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10chttp://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10cTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Osteoarthritis (OA) Transforming growth factor b1 (TGFb1; TGFB1); TGFb…Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10dhttp://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10dTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Interleukin-6 (IL-6); interleukin-8 (IL-8; CXCL8) Mouse and cell …Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10ehttp://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10eTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Histone deacetylase 6 (HDAC6); histone deacetylase 8 (HDAC8) In vitro …Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10fhttp://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10fTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Nuclear receptor subfamily 5 group A member 2 (NR5A2; LRH-1) Mouse and in …Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10ghttp://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10gTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Phosphodiesterase d subunit (PDEd); Ras Mouse studies suggest inhibiting …Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10hhttp://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10hTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colon cancer p53 Mouse and cell culture studies suggest gain-of-function …Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10ihttp://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10iTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Pyruvate dehydrogenase kinase 1 (PDK1) Cell culture and mouse studies …Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10jhttp://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10jTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Sarcoma Sphingosine 1-phosphate (S1P); S1P receptor 1 (S1PR1; S1P1; EDG1) Cell …Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10khttp://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10kTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Infertility Phosphoinositide 3-kinase (PI3K); phosphatase and…Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10lhttp://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10lTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection; candidiasis; malaria Poly-N-acetylglucosamine (…Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10mhttp://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10mTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection Toll-like receptor 2 (TLR2); CD14 Patient sample…Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10nhttp://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10nTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Adenylate cyclase 1 (ADCY1; AC1); NMDA receptor NR2B subtype (GRIN2B; NR2B…Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10ohttp://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10oTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD) a-Synuclein (SNCA) In vitro fruit fly and mouse …Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10phttp://www.biocentury.com/scibx/therapeutics/2013-06-13/the-distillery-therapeutics-s10pTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Transplantation Transplant Thrombopoietin (TPO) receptor (CD110; Mpl) Mouse studies …Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/translationalnotes/2013-06-13/translational-notes-uprooting-ceedd-s4ahttp://www.biocentury.com/scibx/translationalnotes/2013-06-13/translational-notes-uprooting-ceedd-s4aTranslational NotesAlthough GlaxoSmithKline has quietly shuttered its Center of Excellence for External Drug Discovery, the pharma maintains it is not deprioritizing early program partnerships. Rather, GSK has shifted the establishment of…Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/translationalnotes/2013-06-13/uprooting-ceedd-figure-1-selected-deals-between-gsk-and-biotechs-or-academic-institutions-s4bhttp://www.biocentury.com/scibx/translationalnotes/2013-06-13/uprooting-ceedd-figure-1-selected-deals-between-gsk-and-biotechs-or-academic-institutions-s4bTranslational NotesUprooting CEEDD Figure 1. Selected deals between GSK and biotechs or academic institutions. GlaxoSmithKline plc created the Center of Excellence for External Drug Discovery (CEEDD) in 2005 and closed the unit in 2012…Thu, 13 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/coverstory/2013-06-06/cover-story-driving-cancer-through-erbb3-s1http://www.biocentury.com/scibx/coverstory/2013-06-06/cover-story-driving-cancer-through-erbb3-s1Cover StoryGenentech researchers show that mutations in ERBB3 can drive oncogenesis in a process dependent on the receptor's ability to form a heterodimer with HER2. The findings suggest existing HER2-targeted therapies also could…Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/coverstory/2013-06-06/driving-cancer-through-erbb3-figure-1-model-of-oncogenesis-driven-by-mutant-erbb3-s3http://www.biocentury.com/scibx/coverstory/2013-06-06/driving-cancer-through-erbb3-figure-1-model-of-oncogenesis-driven-by-mutant-erbb3-s3Cover StoryCover Story: Driving cancer through ErbB3 Figure 1. Model of oncogenesis driven by mutant ErbB3. Epidermal growth factor receptor 3 (EGFR3; HER3; ErbB3) is a receptor tyrosine kinase that is ineffective at activating…Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/coverstory/2013-06-06/driving-cancer-through-erbb3-table-1-targeted-therapies-against-her2-and-erbb3-s4http://www.biocentury.com/scibx/coverstory/2013-06-06/driving-cancer-through-erbb3-table-1-targeted-therapies-against-her2-and-erbb3-s4Cover StoryCover Story: Driving cancer through ErbB3 Table 1. Targeted therapies against HER2 and ErbB3. In Jaiswal et al., researchers report data suggesting that cancers driven by oncogenic mutations in epidermal growth …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/targetsmechanisms/2013-06-06/targets-and-mechanisms-nanoparticles-for-the-flu-s8http://www.biocentury.com/scibx/targetsmechanisms/2013-06-06/targets-and-mechanisms-nanoparticles-for-the-flu-s8Targets & MechanismsAn NIH team has created a self-assembling influenza nanoparticle that induces the production of antibodies against a wider range of flu strains than traditional vaccines. The next step is immunogenicity testing in …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/targetsmechanisms/2013-06-06/targets-and-mechanisms-watching-obesity-on-a-new-channel-s7http://www.biocentury.com/scibx/targetsmechanisms/2013-06-06/targets-and-mechanisms-watching-obesity-on-a-new-channel-s7Targets & MechanismsUC-Irvine researchers have found that an inhibitor of the potassium channel Kv1.3, a known autoimmunity target, may represent a new class of therapeutic for treating obesity-related diseases. The team has licensed the …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-06-06/the-distillery-techniques-s15ahttp://www.biocentury.com/scibx/techniques/2013-06-06/the-distillery-techniques-s15aTechniquesApproach Summary Licensing status Publication and contact information Disease models Clustered, regularly interspaced short palindromic repeats (CRISPR)-based editing system for one-step production of multigene …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-06-06/the-distillery-techniques-s15bhttp://www.biocentury.com/scibx/techniques/2013-06-06/the-distillery-techniques-s15bTechniquesApproach Summary Licensing status Publication and contact information Disease models Modeling skeletal muscle deficits in Huntington's disease (HD) Mouse muscle fibers could be useful for modeling HD-associated …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-06-06/the-distillery-techniques-s15chttp://www.biocentury.com/scibx/techniques/2013-06-06/the-distillery-techniques-s15cTechniquesApproach Summary Licensing status Publication and contact information Disease models Mouse model for autosomal-dominant leukodystrophy (ADLD) A mouse model for adult-onset ADLD could be useful for identifying …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-06-06/the-distillery-techniques-s15dhttp://www.biocentury.com/scibx/techniques/2013-06-06/the-distillery-techniques-s15dTechniquesApproach Summary Licensing status Publication and contact information Disease models Mouse model for partner and localizer of Brca2 (Palb2)-deficient breast cancer A mouse model for Palb2-deficient breast cancer…Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-06-06/the-distillery-techniques-s15ehttp://www.biocentury.com/scibx/techniques/2013-06-06/the-distillery-techniques-s15eTechniquesApproach Summary Licensing status Publication and contact information Drug platforms Direct conversion of fibroblasts to insulin-secreting cells using DNA demethylating agents In vitro and mouse studies suggest …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-06-06/the-distillery-techniques-s15fhttp://www.biocentury.com/scibx/techniques/2013-06-06/the-distillery-techniques-s15fTechniquesApproach Summary Licensing status Publication and contact information Drug platforms Humanized shark variable new antigen receptors (VNARs) Humanized versions of VNARs could be used to bind protein epitopes that…Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-06-06/the-distillery-techniques-s15ghttp://www.biocentury.com/scibx/techniques/2013-06-06/the-distillery-techniques-s15gTechniquesApproach Summary Licensing status Publication and contact information Imaging High-density lipoprotein (HDL)-mimicking nanoparticles to detect vulnerable atherosclerotic plaques In vitro and rat studies …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-06-06/the-distillery-techniques-s15hhttp://www.biocentury.com/scibx/techniques/2013-06-06/the-distillery-techniques-s15hTechniquesApproach Summary Licensing status Publication and contact information Instrumentation Poly(carboxybetaine methacrylate) (PCBMA), zwitterionic hydrogels to coat implantable devices Mouse studies identified PCBMA …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-06-06/the-distillery-techniques-s15ihttp://www.biocentury.com/scibx/techniques/2013-06-06/the-distillery-techniques-s15iTechniquesApproach Summary Licensing status Publication and contact information Markers G-CSF receptor (CSF3R; CD114) mutations to guide diagnosis and treatment of atypical chronic myelogenous leukemia (aCML) and chronic …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10ahttp://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10aTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Epidermal growth factor receptor 3 (EGFR3; HER3; ErbB3); HER2 (EGFR2; ErbB2; neu) Patient sample and …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10bhttp://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10bTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Integrin a4b1 (CD49D/CD29) Human and mouse studies suggest inhibiting integrin a4b1 could help …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10chttp://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10cTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Poliovirus receptor-related 4 (PVRL4) In vitro and mouse studies suggest inhibiting PVRL4 could help …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10dhttp://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10dTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Thrombospondin-1 (TSP-1; THBS1); prosaposin (PSAP) Cell-based and mouse studies suggest increasing …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10ehttp://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10eTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Tumor necrosis factor receptor 1 (TNFRSF1A; TNFR1; CD120a) A study in mice suggests decreasing …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10fhttp://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10fTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic lymphocytic leukemia (CLL) RAD51 homolog (RAD51); activation-induced cytidine deaminase (AICDA; AID)…Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10ghttp://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10gTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma VEGF receptor 2 (KDR/Flk-1; VEGFR-2) Mouse studies suggest co-delivery of engineered T cells …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10hhttp://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10hTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiomyopathy; heart failure Growth differentiation factor 11 (GDF11) Studies in mice …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10ihttp://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10iTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Fatty acid binding protein 4 adipocyte (FABP4) In vitro and mouse studies …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10jhttp://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10jTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Hematology Hemophilia Factor VIII Mouse studies suggest phosphatidylserine-bound factor VIII could help treat …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10khttp://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10kTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation Dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-SIGN; CD209) Cell culture and …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10lhttp://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10lTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Peripheral benzodiazepine receptor (TSPO; PBR) Mouse studies suggest TSPO …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10mhttp://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10mTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Depression Protocadherin 17 (PCDH17) Mouse and nonhuman primate studies suggest inhibiting PCDH17 could …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10nhttp://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10nTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Other Progeria Isoprenylcysteine carboxyl methyltransferase (ICMT) Mouse and cell culture studies suggest …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10ohttp://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10oTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Cystic fibrosis (CF) Cystic fibrosis transmembrane conductance regulator (CFTR) In vitro and cell…Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10phttp://www.biocentury.com/scibx/therapeutics/2013-06-06/the-distillery-therapeutics-s10pTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Transplantation Graft-versus-host disease (GvHD) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/translationalnotes/2013-06-06/translational-notes-not-so-fast-track-s5http://www.biocentury.com/scibx/translationalnotes/2013-06-06/translational-notes-not-so-fast-track-s5Translational NotesGSK's Discovery Fast Track Competition, which aims to establish direct collaborations with academic researchers, hit a road block when the UCLA Office of Intellectual Property said that UCLA researchers cannot …Thu, 06 Jun 2013 00:00:00 -0700http://www.biocentury.com/scibx/coverstory/2013-05-30/cover-story-rons-new-role-s1http://www.biocentury.com/scibx/coverstory/2013-05-30/cover-story-rons-new-role-s1Cover StoryA Utah team has shown that inhibiting the kinase RON could fight cancer metastasis by stimulating an antitumor immune response. The findings build a case for focusing drug discovery efforts specifically against the …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/targetsmechanisms/2013-05-30/targets-and-mechanisms-doubts-about-targretin-in-ad-s4http://www.biocentury.com/scibx/targetsmechanisms/2013-05-30/targets-and-mechanisms-doubts-about-targretin-in-ad-s4Targets & MechanismsLast year, a widely publicized report by Case Western researchers suggested the cancer drug Targretin could be useful for treating AD. Now, studies by four independent academic teams have failed to replicate some …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-05-30/the-distillery-techniques-s15ahttp://www.biocentury.com/scibx/techniques/2013-05-30/the-distillery-techniques-s15aTechniquesThis week in techniques Approach Summary Licensing status Publication and contact information Assays & screens Small molecule fruit fly screening platform for regulators of sleep A small molecule fruit fly …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-05-30/the-distillery-techniques-s15bhttp://www.biocentury.com/scibx/techniques/2013-05-30/the-distillery-techniques-s15bTechniquesThis week in techniques Approach Summary Licensing status Publication and contact information Assays & screens Whole-exome sequencing to identify antigens for adoptively transferred, autologous tumor-…Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-05-30/the-distillery-techniques-s15chttp://www.biocentury.com/scibx/techniques/2013-05-30/the-distillery-techniques-s15cTechniquesThis week in techniques Approach Summary Licensing status Publication and contact information Disease models Human embryonic stem cells (hESCs) derived from somatic cell nuclear transfer (SCNT) SCNT could be …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-05-30/the-distillery-techniques-s15dhttp://www.biocentury.com/scibx/techniques/2013-05-30/the-distillery-techniques-s15dTechniquesThis week in techniques Approach Summary Licensing status Publication and contact information Drug delivery Transferrin-coated, brain-penetrant gold nanoparticles Mouse studies suggest transferrin-coated gold …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-05-30/the-distillery-techniques-s15ehttp://www.biocentury.com/scibx/techniques/2013-05-30/the-distillery-techniques-s15eTechniquesThis week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Efficient generation of seed virus for production of synthetic influenza vaccines A synthetic …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-05-30/the-distillery-techniques-s15fhttp://www.biocentury.com/scibx/techniques/2013-05-30/the-distillery-techniques-s15fTechniquesThis week in techniques Approach Summary Licensing status Publication and contact information Drug platforms IL-15 and soluble IL-15 receptor a-chain (sIL-15RA) heterodimers Mouse studies suggest heterodimers …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-05-30/the-distillery-techniques-s15ghttp://www.biocentury.com/scibx/techniques/2013-05-30/the-distillery-techniques-s15gTechniquesThis week in techniques Approach Summary Licensing status Publication and contact information Markers Genetic markers underlying respiratory droplet transmission of influenza virus Reverse genetics and guinea …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10ahttp://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10aTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Aldehyde dehydrogenase 1 family member A3 (ALDH1A3) Patient sample …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10bhttp://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10bTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Baculoviral IAP repeat- containing 2 (BIRC2; cIAP1); cIAP2 (BIRC3); diablo…Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10chttp://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10cTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Lysine-specific demethylase 4A (KDM4A; JMJD2A); jun (AP1) proto-oncogene …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10dhttp://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10dTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Macrophage stimulating 1 receptor c-Met-related tyrosine kinase (MST1R; RON…Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10ehttp://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10eTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Mdm2 p53 binding protein homolog (MDM2; HDM2); p53 In vitro and mouse …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10fhttp://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10fTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Signal transducer and activator of transcription 3 (STAT3) In vitro and …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10ghttp://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10gTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Ovarian cancer Nicotinamide phosphoribosyl transferase (NAMPT; NamPRT) In vitro …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10hhttp://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10hTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Thrombosis Peptidyl arginine deiminase type IV (PADI4; PAD4) …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10ihttp://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10iTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes; obesity Not applicable Mouse studies suggest …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10jhttp://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10jTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Staphylococcus Accessory gene regulator cognate receptor (AgrC …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10khttp://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10kTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Bone repair Myocilin (MYOC) Cell culture and mouse studies …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10lhttp://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10lTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Legumain (LGMN; AEP) Patient sample, tissue culture …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10mhttp://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10mTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Depression Not applicable Mouse studies suggest increasing ATP release from …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10nhttp://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10nTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Depression Serum/glucocorticoid regulated kinase 1 (SGK1) Patient, rodent and …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10ohttp://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10oTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Sirtuin 1 (SIRT1) In vitro and mouse studies suggest inhibiting …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10phttp://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10pTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD) Adenosine A2A receptor (ADORA2A); monoamine oxidase B…Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10qhttp://www.biocentury.com/scibx/therapeutics/2013-05-30/the-distillery-therapeutics-s10qTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Age-related macular degeneration (AMD); retinitis PC4 and SFRS1-…Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/tools/2013-05-30/optimizing-transferrin-mediated-transcytosis-figure-1-model-of-receptor-mediated-transcytosis-of-transferrin-containing-nanoparticles-s8http://www.biocentury.com/scibx/tools/2013-05-30/optimizing-transferrin-mediated-transcytosis-figure-1-model-of-receptor-mediated-transcytosis-of-transferrin-containing-nanoparticles-s8ToolsOptimizing transferrin-mediated transcytosis Figure 1. Model of receptor-mediated transcytosis of transferrin-containing nanoparticles. Transferrin and its receptor are one of the ligand-receptor combinations that …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/tools/2013-05-30/tools-optimizing-transferrin-mediated-transcytosis-s7http://www.biocentury.com/scibx/tools/2013-05-30/tools-optimizing-transferrin-mediated-transcytosis-s7ToolsCaltech researchers have shown how modulating the transferrin content on gold nanoparticles can optimize their delivery into the brain via the transferrin receptor. The group now needs to determine whether its strategy …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/tools/2013-05-30/tools-synthetic-influenza-seeds-s6http://www.biocentury.com/scibx/tools/2013-05-30/tools-synthetic-influenza-seeds-s6ToolsAn international team led by Novartis and the J. Craig Venter Institute has improved the speed and accuracy of seed influenza virus production for large-scale vaccine manufacture. Adoption of the platform could shave …Thu, 30 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/coverstory/2013-05-23/cover-story-irs-audit-for-tumors-s1http://www.biocentury.com/scibx/coverstory/2013-05-23/cover-story-irs-audit-for-tumors-s1Cover StoryAn Israeli academic-industry partnership has discovered small molecules that target insulin receptor substrates 1 and 2, which sit downstream of the cancer-associated insulin-like growth factor-1 receptor. The compounds…Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-05-23/the-distillery-techniques-s16ahttp://www.biocentury.com/scibx/techniques/2013-05-23/the-distillery-techniques-s16aTechniquesApproach Summary Licensing status Publication and contact information Assays & screens Fluorescence labels in phosphatase (FLiP) assay to detect allosteric inhibitors of phosphatases A FLiP assay could help …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-05-23/the-distillery-techniques-s16bhttp://www.biocentury.com/scibx/techniques/2013-05-23/the-distillery-techniques-s16bTechniquesApproach Summary Licensing status Publication and contact information Disease models Postsurgical resection model for metastatic breast cancer A mouse model for postsurgical resection metastatic breast cancer …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-05-23/the-distillery-techniques-s16chttp://www.biocentury.com/scibx/techniques/2013-05-23/the-distillery-techniques-s16cTechniquesApproach Summary Licensing status Publication and contact information Drug delivery Collagen-like, cell-penetrating peptides for drug delivery Cell-penetrating peptides structurally similar to collagen could be …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-05-23/the-distillery-techniques-s16dhttp://www.biocentury.com/scibx/techniques/2013-05-23/the-distillery-techniques-s16dTechniquesApproach Summary Licensing status Publication and contact information Drug delivery Improved safety for blood brain barrier (BBB)-penetrating antibodies Mouse studies suggest bispecific antibodies that cross the…Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-05-23/the-distillery-techniques-s16ehttp://www.biocentury.com/scibx/techniques/2013-05-23/the-distillery-techniques-s16eTechniquesApproach Summary Licensing status Publication and contact information Drug delivery Using modified hyperbranched polyglycerol (HPG) to guide stem cell localization Modified HPG could be used to target injected …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-05-23/the-distillery-techniques-s16fhttp://www.biocentury.com/scibx/techniques/2013-05-23/the-distillery-techniques-s16fTechniquesApproach Summary Licensing status Publication and contact information Drug platforms N-Glycosylation of Fc regions to improve antibody half-life and specificity In vitro studies yielded a monomeric Fc fragment …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-05-23/the-distillery-techniques-s16ghttp://www.biocentury.com/scibx/techniques/2013-05-23/the-distillery-techniques-s16gTechniquesApproach Summary Licensing status Publication and contact information Drug platforms Scaffolds with endothelial cell cords to promote vascularization of tissue transplants Mouse studies suggest scaffolds …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-05-23/the-distillery-techniques-s16hhttp://www.biocentury.com/scibx/techniques/2013-05-23/the-distillery-techniques-s16hTechniquesApproach Summary Licensing status Publication and contact information Markers Adrenomedullin (ADM; AM) and calcitonin receptor-like (CRLR; CALCRL) levels to diagnose pre-eclampsia Mouse studies suggest …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2013-05-23/the-distillery-techniques-s16ihttp://www.biocentury.com/scibx/techniques/2013-05-23/the-distillery-techniques-s16iTechniquesApproach Summary Licensing status Publication and contact information Markers Classification system for endometrial cancers In vitro studies were used to develop a classification system for endometrial cancers …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10ahttp://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10aTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute myelogenous leukemia (AML) AML1-ETO oncogenic fusion protein; cyclooxygenase-2 (COX-2) In vitro and …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10bhttp://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10bTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer B cell lymphoma Histone deacetylase (HDAC); proteasome Cell culture and mouse studies suggest a combination …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10chttp://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10cTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Integrin b1 (CD29) In vitro and mouse studies suggest CD29 inhibitors could help treat Avastin …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10dhttp://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10dTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Ret proto-oncogene (RET) Studies in cell culture suggest inhibiting RET could be useful for …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10ehttp://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10eTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Ribosomal protein S6 kinase 90 kDa polypeptide 2 (RPS6KA2; RSK3); RPS6KA6 (RSK4); …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10fhttp://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10fTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Fibroblast activation protein (FAP) In vitro studies identified a boronic acid-based inhibitor of FAP…Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10ghttp://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10gTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Heat shock protein 90 (Hsp90); lysine-specific demethylase 4B (KDM4B; JMJD2B) Cell culture studies …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10hhttp://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10hTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer HER2 (EGFR2; ErbB2; neu) Mouse and cell culture studies have identified a HER2-specific aptamer that …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10ihttp://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10iTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer TTK protein kinase (TTK; MPS1) In vitro and rat studies suggest a new class of MPS1 inhibitors could …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10jhttp://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10jTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Tubulin A mouse study suggests photodynamic therapy (PDT) with red light-activated prodrugs could …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10khttp://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10kTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Leukemia Telomerase reverse transcriptase (TERT) A mouse study suggests adoptive transfer of T cells …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10lhttp://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10lTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Solid tumors Insulin-like growth factor-1 receptor (IGF1R; CD221); insulin receptor substrate 1 (IRS1); IRS2…Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10mhttp://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10mTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Depression; pain Regulator of G-protein signaling 4 (RGS4) Mouse studies suggest modulating RGS4 …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10nhttp://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10nTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Histone deacetylase 2 (HDAC2) Mouse studies suggest inhibiting HDAC2 in the brain could help …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10ohttp://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10oTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Other Cushing's disease Nuclear receptor subfamily 2 group C member 2 (NR2C2; TR4) Patient sample and mouse …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10phttp://www.biocentury.com/scibx/therapeutics/2013-05-23/the-distillery-therapeutics-s10pTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Various Bacterial infections; inflammation Lipopolysaccharide (LPS) Cell culture studies suggest a cathelicidin …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/tools/2013-05-23/finding-a-home-for-nuclear-transfer-table-1-stem-cell-types-and-methods-for-stem-cell-generation-s8http://www.biocentury.com/scibx/tools/2013-05-23/finding-a-home-for-nuclear-transfer-table-1-stem-cell-types-and-methods-for-stem-cell-generation-s8ToolsTools: Finding a home for nuclear transfer Table 1. Stem cell types and methods for stem cell generation. There are three major classes of stem cells: embryonic stem cells (ESCs), induced pluripotent stem (iPS) cells…Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/tools/2013-05-23/tools-finding-a-home-for-nuclear-transfer-s7http://www.biocentury.com/scibx/tools/2013-05-23/tools-finding-a-home-for-nuclear-transfer-s7ToolsOregon Health & Science University researchers have for the first time generated stable lines of human embryonic stem cells via somatic cell nuclear transfer. Whether the platform can carve a niche among existing stem …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/tools/2013-05-23/tools-revisiting-adrenomedullin-in-pre-eclampsia-s5http://www.biocentury.com/scibx/tools/2013-05-23/tools-revisiting-adrenomedullin-in-pre-eclampsia-s5ToolsA North Carolina team has shown that fetal deficiency in adrenomedullin resulted in mouse placental abnormalities similar to those found in pre-eclampsia. The results point to adrenomedullin as a potential marker for …Thu, 23 May 2013 00:00:00 -0700http://www.biocentury.com/scibx/translationalnotes/2013-05-23/translational-notes-oxford-goes-big-(data)-s4http://www.biocentury.com/scibx/translationalnotes/2013-05-23/translational-notes-oxford-goes-big-(data)-s4Translational NotesUniversity of Oxford is bringing big data to translational research. The university, the U.K. government and a philanthropist are infusing up to L90 million ($138.3 million) to set up a new hub that will use large-scale…Thu, 23 May 2013 00:00:00 -0700